» Articles » PMID: 37887559

Neuroblastoma Interaction with the Tumour Microenvironment and Its Implications for Treatment and Disease Progression

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2023 Oct 27
PMID 37887559
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma, a paediatric malignancy of the peripheral nervous system, displays a wide range of clinical outcomes, including regression to fatality despite extensive treatment. Neuroblastoma tumours display a complex interplay with their surrounding environment, known as the tumour microenvironment, which may affect disease progression and patient prognosis. This study aimed to dissect the ways in which neuroblastoma biology, treatment, prognosis, progression, and relapse are linked with the extracellular matrix, the dichotomous identities of neuroblastoma, various regulatory proteins and RNA, and extracellular vesicles within the backdrop of the tumour microenvironment. In addition, other aspects, such as immune cell infiltration, therapeutic options including monoclonal antibodies and small molecule inhibitors; and the ways in which these may affect disease progression and immunosuppression within the context of the neuroblastoma tumour microenvironment, are addressed. Such studies may shed light on useful therapeutic targets within the tumour microenvironment that may benefit groups of NB patients. Ultimately, a detailed understanding of these aspects will enable the neuroblastoma scientific community to improve treatment options, patient outcomes, and quality of life.

Citing Articles

Global, regional and national burden of neuroblastoma and other peripheral nervous system tumors, 1990 to 2021 and predictions to 2035: visualizing epidemiological characteristics based on GBD 2021.

Yue C, Zhang Q, Sun F, Pan Q Neoplasia. 2025; 60:101122.

PMID: 39855015 PMC: 11795104. DOI: 10.1016/j.neo.2025.101122.


Immune-oncology targets and therapeutic response of cell pyroptosis-related genes with prognostic implications in neuroblastoma.

Liu X, Xu Z, Yin H, Zhao X, Duan J, Zhou K Discov Oncol. 2024; 15(1):661.

PMID: 39548036 PMC: 11568093. DOI: 10.1007/s12672-024-01518-8.

References
1.
Discher D, Janmey P, Wang Y . Tissue cells feel and respond to the stiffness of their substrate. Science. 2005; 310(5751):1139-43. DOI: 10.1126/science.1116995. View

2.
Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke J . Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021; 9(7). PMC: 8287618. DOI: 10.1136/jitc-2021-002417. View

3.
Davis K, Fox E, Merchant M, Reid J, Kudgus R, Liu X . Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020; 21(4):541-550. PMC: 7255545. DOI: 10.1016/S1470-2045(20)30023-1. View

4.
Mills C, Benton T, Pina I, Francis M, Reyes L, Dolloff N . Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma. Chem Sci. 2023; 14(8):2168-2182. PMC: 9945084. DOI: 10.1039/d2sc05749b. View

5.
Kameneva P, Artemov A, Kastriti M, Faure L, Olsen T, Otte J . Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat Genet. 2021; 53(5):694-706. PMC: 7610777. DOI: 10.1038/s41588-021-00818-x. View